

UTILITY PATENT
APPLICATION TRANSMITTAL
(Under 37 C.F.R. §1.53(b))

Docket No.: VAS-5041CIP1 Page 1 of 2
Title: Radially Expandable Tubular Stented Grafts
Express Mail Label No.: EL599141795US

APPLICATION ELEMENTS

INVENTORS: Donald T. Shannon, Chris Kuo, Benny Tu

ADDRESS TO: Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

<input checked="" type="checkbox"/>	Fee Transmittal Form (Submit an original, and a duplicate for fee processing)					
2.	<input checked="" type="checkbox"/>	Specification	[Total Pages 50]			
3.	<input checked="" type="checkbox"/>	Drawing(s) (35 USC §113)	[Total Pages (Figs.1-8a) 5]			
4.	<input checked="" type="checkbox"/>	Signed Declaration	[Total Pages 3]			
	a. <input type="checkbox"/>	Newly executed (original or copy)				
	b. <input checked="" type="checkbox"/>	Copy from a prior application (37 CFR §1.63(d))				
	(Note Box 5 below)					
	i. <input checked="" type="checkbox"/>	<u>DELETION OF INVENTOR(S)</u>				
	Signed statement attached deleting inventor named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b)					
5.	<input type="checkbox"/>	Incorporation By Reference (useable if Box 4b is checked.) entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein				
6.	<input type="checkbox"/>	Microfiche Computer Program				
7.	<input type="checkbox"/>	Nucleotide and/or Amino Acid Sequence Submission				
8.	<input type="checkbox"/>	Assignment Papers with recordation sheet (<u> </u> pages)				
9.	<input type="checkbox"/>	37 CFR §3.73(b) Statement	<input type="checkbox"/> Power of Attorney			
10.	<input type="checkbox"/>	English Translation Document				
17.	If a CONTINUING APPLICATION, check appropriate box and supply information					
	<input type="checkbox"/>	Continuation	<input type="checkbox"/>	Divisional	<input checked="" type="checkbox"/>	Continuation-Invention
18.	The present application claims priority under 35 USC § 119 to U.S. Application No. _____ filed _____					

11. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations

12. Preliminary Amendment

13. Return Receipt Postcard (MPEP 503) 
14. Small Entity Statement(s) 1000 U.S. Pro
10/001765

15. Certified Copy of Priority Documents (s)

16a. Cancel in the application original claims _____ before calculating the filing fee

16b. Amend the specification by inserting before the first line the sentence: --This is a _____ Continuation, _____ Divisional, _____ Continuation-in-part, of application _____, filed _____

16c. I hereby verify that the attached papers are a true copy of the latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was Signed. I hereby verify that the papers are a true copy of the latest signed prior application number _____, filed _____ and further that all statements made herein of my own knowledge are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

16d. Other: Deletion of Inventors

16e. Other: Request for Non-Publication of Application

16e. Other: Request for Non-Publication of Application

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: 09/358,350

18. The present application claims priority under 35 USC § 119 to U.S. Provisional Application No. _____, filed _____.

UTILITY PATENT
APPLICATION TRANSMITTAL
(Under 37 C.F.R. §1.53(b))


Docket No.: VAS-5041CIP1 Page 2 of 2
Title: Radially Expandable Tubular Stented Grafts
Express Mail Label No.: EL599141795US

CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(b))	113 - 20=	93	X \$18 =	\$1,674
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	3 - 3=	0	\$84 =	\$0
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR §1.16(d))			+ \$ 280 =	\$ 0
				BASIC FEE (37 CFR §1.16(a))	\$740
				TOTAL =	\$2,414

The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to Deposit Account No. 501225 (Docket VAS-5041CIP1)
(For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- a. Fees required under 37 CFR §1.16
- b. Fees required under 37 CFR §1.17
- c. Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

NAME	Peter J. Gluck, Reg. No. 38,022
SIGNATURE	
DATE	October 31, 2001

CORRESPONDENCE ADDRESS

Edwards Lifesciences LLC
Law Dept.
One Edwards Way
Irvine, California 92614
Telephone: (949) 250-6801 Fax: (949) 250-6850

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.10

I hereby certify that the above-identified document is being deposited with the United States Postal Service as Express Mail No. EL599141795US in an envelope addressed to Box Patent Application, Commissioner for Patents, Washington, D.C. 20231 on October 31, 2001.

By: 
Jan Lamonica